

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Management of inflammatory bowel disease during COVID-19 pandemic

### This is the author's manuscript

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1747966> since 2020-09-13T09:11:05Z

*Published version:*

DOI:10.23736/S1121-421X.20.02707-5

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

## **Management of inflammatory bowel disease during COVID-19 pandemic**

Journal: Minerva Gastroenterologica e Dietologica

Paper code: Minerva Gastroenterol Dietol-2707

Submission date: April 8, 2020

Article type: Editorial

Files:

1. Manuscript

Version: 1

Description: manoscritto

File format: application/msword

1 **Management of inflammatory bowel disease during COVID-19 pandemic**

2  
3  
4  
5  
6 Davide Giuseppe Ribaldone <sup>1\*</sup>, Marco Astegiano <sup>2</sup>, Giovanni Clemente Actis <sup>3</sup>, Rinaldo Pellicano <sup>2</sup>

7  
8  
9  
10  
11 <sup>1</sup>Department of Medical Sciences, Division of Gastroenterology, University of Turin, Turin, Italy;

12  
13 <sup>2</sup>Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette-SGAS Hospitals,  
14  
15 10126 Turin, Italy

16  
17  
18 <sup>3</sup>The Medical Center Practice Office, Turin, Italy

19  
20  
21  
22 Conflicts of interest: none to declare.

23  
24  
25  
26  
27  
28 \*Corresponding author: Davide Giuseppe Ribaldone - Department of Medical Sciences, Division of  
29  
30 Gastroenterology, University of Turin, C.so Bramante 88 - 10126 Torino – Italy. E-mail:  
31  
32 davrib\_1998@yahoo.com Tel: +390116333918, Fax: +390116333623.

33  
34  
35  
36  
37  
38 **Key words:** 2019-nCoV - Crohn's disease – SARS-CoV-2 - Telemedicine - Ulcerative colitis

1 The new coronavirus pandemic, called COVID-19 (CoV-2), originated in China around November  
2  
3  
4 2019 and has gradually spread all over the world, upsetting our lives. To date (April 4, 2020) more than  
5  
6 1 million people in the world have tested positive (and 10 times as many are likely to be infected) and  
7  
8 around 60,000 have died (this figure also seems highly underestimated), Italy ranks first in this list, and  
9  
10 the number of new infections is still increasing steadily. Mortality, which in Italy has exceeded 12% of  
11  
12 the infected, seems to be conditioned by the presence of comorbidities such as high blood pressure,  
13  
14 diabetes, chronic bronchitis.<sup>1</sup> Thus, these conditions lead to frailty of the affected patients.<sup>2,3</sup>  
15  
16  
17 Inflammatory bowel diseases (IBDs) are not mentioned among these conditions.  
18  
19

20 IBDs are immune-mediated diseases in which a dysregulated reaction of the immune system towards  
21  
22 the intestinal microbiome induces a chronic inflammation that causes progressive damage. Despite an  
23  
24 inflammatory core centred on the bowel,<sup>4</sup> IBDs could be associated to several extra-intestinal  
25  
26 manifestations.<sup>5</sup> These diseases particularly affect young people, requiring a chronic management as  
27  
28 well as the use of immunosuppressant and biological drugs<sup>6</sup> raising obvious safety issues.  
29  
30

31 Furthermore, the digestive tract does not appear to be immune from COVID-19 involvement. The  
32  
33 antagonist angiotensin-converting enzyme 2 (ACE2), which main function is to negatively regulate the  
34  
35 renin-angiotensin system, is the COVID-19 gate to our cells.<sup>7</sup> Lung, kidney, and gut cells all express  
36  
37 ACE2 receptors. Not surprisingly, gastrointestinal symptoms are part (albeit with limited clinical  
38  
39 importance) of the expression of the infection from severe acute respiratory syndrome (SARS)-CoV-2.<sup>8</sup>  
40  
41  
42

43 To date, April 4, 2020, more than 275 cases of IBD patients infected by COVID-19 are reported  
44  
45 worldwide.<sup>9</sup> Obviously, we do not yet have data to know whether IBD patients are at an increased risk  
46  
47 of COVID-19 infection due to the disease itself or because of the drugs they are treated with.<sup>10</sup> In this  
48  
49 perspective, a study published in 2009 could be informative. The authors used two mouse models  
50  
51 permissive for a coronavirus experimental infection. Essentially, it was found that older but not  
52  
53  
54  
55

1 younger animals responded with a “cytokine storm” including major pro-inflammatory cytokines and  
2  
3 interferon (IFN), with the older succumbing to this mixture more than the younger.<sup>11</sup> The key message  
4  
5 is that disease behavior does mostly depend on host immunity, with full blown deadly reactions most  
6  
7 probable at advanced age.  
8  
9

10  
11 Coherently with this premise, the preference of IBD for younger age cohorts should reassure us on  
12  
13 their outcomes in COVID infection; the role of medications in this context is mixed, however. The  
14  
15 example of the possible beneficial role of tocilizumab (anti-interleukin-6 drug) in limiting the cytokine  
16  
17 storm is an important example.<sup>12</sup> In this regard, how should we advise our IBD patients?  
18  
19

20  
21 Patients with IBD should not be routinely considered to have an altered immunocompetence per se,  
22  
23 despite evidence of impaired innate mucosal immunity.<sup>13</sup> If we can safely state that our patients can  
24  
25 continue mesalazine therapy without concern, we know that the immunomodulators commonly used in  
26  
27 IBD (corticosteroids, thiopurines, methotrexate, calcineurin inhibitors, anti-Tumor Necrosis Factor  
28  
29 agents and other biologics) are associated with an increased risk of infections, especially if they are  
30  
31 used in combination or in older patients. For corticosteroids, a total daily dose equivalent to  $\geq 20$  mg of  
32  
33 prednisolone for  $\geq 2$  weeks is associated with an increased risk of infections.<sup>14</sup>  
34  
35  
36

37 While the incidence of influenza does not appear greater in patients affected by IBD receiving  
38  
39 immunomodulators, immunosuppression is generally considered to enhance the risk of  
40  
41 severe/complicated influenza infection and immunosuppressed patients with a laboratory diagnosis of  
42  
43 influenza should receive timely treatment early in the course of illness.<sup>14</sup> Withdrawal of immune  
44  
45 suppression is advisable in the case of ascertained COVID-19 infection; yet, preemptive withdrawal is  
46  
47 not wise, if considering a possible severe flare.<sup>15</sup>  
48  
49  
50

51  
52 Chronic IBD patients subjected to long-term treatment on one hand, and physical distancing  
53  
54 measures on the other hand, will make a worsening challenge overcrowding our out-patient facilities.<sup>16</sup>  
55

1 This could be the ideal test opportunity for telemedicine. The use of telemonitoring and teleconsulting  
2  
3  
4 seems to be safe and feasible with excellent patient acceptance.<sup>17</sup> These can be implemented to enhance  
5  
6 monitoring of disease activity and toxicity of therapy and promote empowerment and improvement of  
7  
8 patient quality of life. However, this cannot be done by the individual clinician rather the Health  
9  
10 Authority must fully be involved.  
11

12  
13 In conclusion, COVID superinfection will make a double endeavor on all physicians and IBD  
14  
15 caregivers, reinforcing rules already applied for compromised hosts exposed to infection: prevent  
16  
17 contact with potential sources, avoid starting therapeutic strategies with 2 immunomodulatory drugs,  
18  
19 prompt suspension of these drugs in case of COVID-19 infection.  
20  
21

## 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55

### References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;
2. Zazzara MB, Vetrano DL, Carfi A, Onder G. Frailty and chronic disease. *Panminerva Med*. 2019 Dec 1;61(4):486–92.
3. Petrini E, Caviglia GP, Pellicano R, Saracco GM, Morino M, Ribaldone DG. Risk of drug interactions and prescription appropriateness in elderly patients. *Ir J Med Sci*. 2019;
4. Newman KM, Vaughn BP. Efficacy of intestinal microbiota transplantation in ulcerative colitis: A review of current literature and knowledge. Vol. 65, *Minerva Gastroenterologica e Dietologica*. Edizioni Minerva Medica; 2019. p. 268–79.
5. Ribaldone DG, Pellicano R, Actis GC. The gut and the Inflammatory Bowel Diseases inside-out:

- 1 the extra-intestinal manifestations. *Minerva Gastroenterol Dietol.* 2019 Apr 16;  
2  
3  
4 6. Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. *J*  
5  
6  
7 *Clin Med.* 2019 Nov 14;8(11):1970.  
8  
9 7. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new  
10  
11 potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovasc*  
12  
13 *Res.* 2020 Mar 30;  
14  
15  
16 8. Kotfis K, Skonieczna-Żydecka K. COVID-19: gastrointestinal symptoms and potential sources  
17  
18 of 2019-nCoV transmission. *Anaesthesiol Intensive Ther.* 2020 Mar 23;  
19  
20  
21 9. Current Data | Secure-IBD Database [Internet]. [cited 2020 Apr 4]. Available from:  
22  
23 <https://covidibd.org/current-data/>  
24  
25  
26 10. Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for  
27  
28 Covid-19 infection? *J Crohns Colitis.* 2020 Mar 26;  
29  
30  
31 11. Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman M, et al. Early Upregulation  
32  
33 of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an  
34  
35 Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection. *J Virol.* 2009  
36  
37 Jul 15;83(14):7062–74.  
38  
39  
40 12. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe  
41  
42 COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce  
43  
44 the mortality. *Int J Antimicrob Agents.* 2020 Mar 28;105954.  
45  
46  
47 13. Kmieć Z, Cyman M, Ślebioda TJ. Cells of the innate and adaptive immunity and their  
48  
49 interactions in inflammatory bowel disease. Vol. 62, *Advances in Medical Sciences.* Medical  
50  
51 University of Białystok; 2017. p. 1–16.  
52  
53  
54  
55

- 1 14. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European  
2 evidence-based consensus on the prevention, diagnosis and management of opportunistic  
3 infections in inflammatory bowel disease. *J Crohn's Colitis*. 2014 Jun 1;8(6):443–68.  
4  
5  
6  
7  
8  
9 15. Fiorino G, Allocca M, Furfaro F, Gilardi D, Zilli A, Radice S, et al. Inflammatory bowel disease  
10 care in the COVID-19 pandemic era: the Humanitas, Milan experience. *J Crohns Colitis*. 2020  
11 Mar 24;  
12  
13  
14  
15  
16 16. Ribaldone DG, Adriani A, Caviglia GP, Nicolò A De, Agnesod D, Simiele M, et al. Correlation  
17 between thiopurine S-methyltransferase genotype and adverse events in inflammatory bowel  
18 disease patients. *Med*. 2019;55(8).  
19  
20  
21  
22  
23 17. Peris MA, Del Hoyo J, Bebia P, Faubel R, Barrios A, Bastida G, et al. Telemedicine in  
24 inflammatory bowel disease: Opportunities and approaches. *Inflamm Bowel Dis*. 2015  
25 Feb;21(2):392–9.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55